Instructions for use of Vanzacato/Tizacaftor/Deuterated Ivacaftor Combination Tablets

Vanzacaftor, tezacaftor and deutivacaftor combination tablets (vanzacaftor, tezacaftor and deutivacaftor), trade name Alyftrek, is an innovative triple combination CFTR modulator, providing a new treatment option for patients with cystic fibrosis (CF). The drug is suitable for cystic fibrosis patients aged 6 years and older who carry at least one F508del mutation or other reactive mutations in the CFTR gene. For patients with unknown genotypes, the presence of at least one indicator mutation must be confirmed through an FDA-approved CF mutation test before use. This innovative therapy brings new hope for improving patients' quality of life by targeting and repairing defective CFTR proteins.

The mechanism of action of vanzacator/tizacaftor/Deuterated ivacaftor compound tablets embodies the concept of precision medicine. The three ingredients act synergistically on different sites of the CFTR protein. Vanzacattor and tizacattor respectively bind to different regions of the CFTR protein and jointly promote the transport of defective proteins to the cell surface, while deuterated ivacaftor can enhance the functional activity of these proteins on the cell surface. This triple mechanism of action enables more functional CFTR proteins to be localized to the cell membrane and significantly improves chloride transport function. This effect can be objectively evaluated through laboratory testing and sweat chloride ion concentration measurement. This synergistic effect provides a molecular basis for improving clinical symptoms in patients with cystic fibrosis.

In terms of usage and dosage, vanzakatol/tizacaftor/Deuterated ivacaftor compound tablets needs to be taken with fatty foods to promote absorption. For children aged 6 to under12 years old and weighing less than 40kg, it is recommended to take 3 tablets once a day; and 6 Children aged 12 years to under12 years old and weighing ≥40kg, and patients 12 years old years old and above should be taken orally once a day2piece. If the missed dose is within 6 hours, you should take it immediately. If it exceeds 6 hours, skip the dose and continue taking the medicine as originally planned the next day. It is important to note that all patients must undergo a comprehensive liver function test before treatment, and review it monthly at the beginning of treatment, and then adjust it to every 3 months or once a year according to the situation. This rigorous monitoring program is critical to ensuring medication safety.

Althoughvanzacato/tizakato/deuterated ivacaftor composite tablets has brought significant curative effects to patients with cystic fibrosis, it may also cause a series of adverse reactions. The most common adverse reactions include cough, sore throat, nasopharyngitis, flu-like symptoms, fatigue, upper respiratory tract infection, elevated liver enzymes, rash, headache, and sinus congestion. What deserves more vigilance is the possibility of severe liver damage, which may manifest as right upper quadrant pain, nausea and vomiting, darker urine, jaundice of the skin or sclera, and other symptoms. Once this occurs, you should seek medical attention immediately. In addition, the risk of allergic reactions and cataracts also require special attention, and children and adolescent patients, especially, should undergo eye examinations before and after treatment. These potential adverse reactions require both doctors and patients to be highly vigilant.

When using vanzacato/tizakato/deuterated ivacaftor combination tablets, there are several key considerations to keep in mind. First of all, this product is contraindicated in patients with severe hepatic impairment (Child-Pugh C grade). Patients with moderate hepatic impairment (Child-Pugh B grade) need to carefully evaluate the risk-benefit ratio when using it. Secondly, the drug has significant interactions with CYP3A inducers or inhibitors: strong or moderate CYP3A inducers will reduce drug concentration and affect efficacy, and should be avoided in combination; while CYP3A inhibitors will increase drug exposure and may enhance adverse reactions, so dosage adjustment needs to be considered. Finally, for those who have discontinued drugs containing elexacaftor, tezacaftor or ivacaftor due to adverse reactions in the past For patients, the risk-to-benefit ratio must be fully evaluated before using vanzacato/tizakato/Deuterated ivacaftor composite tablets and closely monitored during use.

The storage conditions of vanzacator/tizacator/deuterated ivacaftor composite tablets require room temperature (20-25℃) to ensure drug stability. It is worth noting that it is currently unclear whether the drug will affect 6Safety and effectiveness in children under 20 years of age, therefore use in this age group is not recommended. As clinical experience accumulates, our understanding of this innovative therapy will continue to deepen and we will provide safer and more effective treatment options for patients with cystic fibrosis. During use, patients should maintain close communication with their doctors and report any abnormal symptoms in a timely manner to ensure the best treatment effect.

Reference link:https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218730s000lbl.pdf